Evidence map›Paper›PMID 19690855›Full record

Trial reportCancer immunology, immunotherapy : CII2010

A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer.

Anda M Vlad, Raluca A Budiu, Diana E Lenzner, Yun Wang, Julia A Thaller, Kelly Colonello, Peggy A Crowley-Nowick, Joseph L Kelley, Fredric V Price, Robert P Edwards

Open access · greenAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer immunology, immunotherapy : CII, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
5.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 83 citations in OpenAlex.

  1. Review
  2. First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Anda M VladDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine, 300 Halket Str, Pittsburgh, PA 15213, USA.
Raluca A Budiu
Diana E Lenzner
Yun Wang
Julia A Thaller
Kelly Colonello
Peggy A Crowley-Nowick
Joseph L Kelley
Fredric V Price
Robert P Edwards
Magee-Womens Hospital · USUniversity of Pittsburgh · USUPMC Hillman Cancer Center · USMagee-Womens Research Institute · US

Funding

PERITONEAL CYTOKINE RESPONSES TO INTERLEUKIN 2 INFUSIONR21CA074105 · NCI · MAGEE-WOMEN'S HOSPITAL OF UPMC · PI EDWARDS, ROBERT P · 1997 to 1999
–
NCI NIH HHS R21 CA74105-02S1
6 · The paper itself

Abstract

Ovarian cancer patients with persistent (platinum-resistant) or progressive (platinum-refractory) disease respond poorly to second line chemotherapy and have low survival expectancy. New and improved therapeutic approaches are needed and immune biologics are one possibility. Interleukin-2 (IL-2) is a T-cell growth factor believed to be important in anti-tumor immunity. We performed a phase II clinical trial with intraperitoneal (IP) recombinant IL-2 administered in weekly infusions of 6 x 10(5) IU/m2. Thirty-one subjects were sequentially entered into the study and clinical responses were surgically confirmed in 24 patients. The primary end point of this study was clinical response with immunologic measurements as secondary end points. The IP regimen was generally well tolerated. Of the 24 patients assessed for response, there were 6 (4 complete, 2 partial) responses for an overall response rate of 25.0% [95% confidence interval (CI) of 11-45]. The median survival of the 31 patient cohort was 2.1 years (95% CI of 1.3-4.4), but for the 6 patients with responses the median survival has not been reached (range 24-120+ months). Eosinophil and lymphocyte numbers were continuously monitored during treatment. Peripheral blood eosinophils were markedly increased at the completion of treatment (p < 0.0001) and associated with increased circulating eotaxin (p = 0.03). We also found significant associations between changes in CD3 counts and survival (p = 0.05) and between IFNγ- secreting CD8 T cells at early time points and survival (p = 0.04). This study provides important evidence for IP IL-2 in platinum-resistant ovarian cancer and identifies several immune correlates of survival.

Indexed as

Drug Resistance, NeoplasmAdultAgedAntineoplastic AgentsEosinophiliaFemaleHumansInjections, IntraperitonealInterleukin-2LymphocytesLymphocytosisMiddle AgedOvarian NeoplasmsPlatinum CompoundsRecombinant ProteinsTreatment OutcomeAntineoplastic AgentsInterleukin-2Platinum CompoundsRecombinant Proteins

Identifiers

PMID19690855
PMCPMC11029832
OpenAlexW2113875809

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.